DOCSLIB.ORG

Statin Myopathy: a Common Dilemma Not Reflected in Clinical Trials

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Statin Myopathy: a Common Dilemma Not Reflected in Clinical Trials REVIEW CME EDUCATIONAL OBJECTIVE: Readers will assess possible statin-induced myopathy in their patients on statins CREDIT GENARO FERNANDEZ, MD ERICA S. SPATZ, MD CHARLES JABLECKI, MD PAUL S. PHILLIPS, MD Internal Medicine Residency Program, Robert Wood Johnson Clinical Scholars Department of Neurosciences, University Director, Interventional Cardiology, The University of Utah, Salt Lake City Program, Cardiovascular Disease Fellow, of California San Diego, La Jolla Department of Cardiology, Scripps Mercy Yale University School of Medicine, New Hospital, San Diego, CA Haven, CT Statin myopathy: A common dilemma not reflected in clinical trials ■■ ABSTRACT hen a patient taking a statin complains Wof muscle aches, is he or she experiencing Although statins are remarkably effective, they are still statin-induced myopathy or some other prob- underprescribed because of concerns about muscle toxic- lem? Should statin therapy be discontinued? Statins have proven efficacy in preventing ity. We review the aspects of statin myopathy that are 1 important to the primary care physician and provide a heart attacks and death, and they are the most guide for evaluating patients on statins who present with widely prescribed drugs worldwide. Neverthe- less, they remain underused, with only 50% of muscle complaints. We outline the differential diagnosis, those who would benefit from being on a statin the risks and benefits of statin therapy in patients with receiving one.2,3 In addition, at least 25% of possible toxicity, and the subsequent treatment options. adults who start taking statins stop taking them 4 ■■ by 6 months, and up to 60% stop by 2 years. KEY POINTS Patient and physician fears about myopathy There is little consensus on the definition of statin-in- remain a key reason for stopping. Myopathy, a duced myopathy, and it is underdiagnosed. The incidence known side effect of statins, is rare in random- of statin-induced muscle toxicity in randomized con- ized controlled trials, but less so in observational studies and clinical experience. This discrepancy trolled trials is lower than in clinical practice. between clinical trials and clinical experience reduces confidence in lipid-lowering therapy and Abnormal pharmacokinetic activity contributes to toxic- contributes to its underuse. ity, but some patients may be predisposed by underlying This review emphasizes clinical aspects metabolic muscle disorders. of statin myopathy that are important to the practicing physician. We will define myopathy, A focused history and neuromusculoskeletal examination review its purported mechanisms, and describe are important in the evaluation of muscle complaints that a clinical approach to patients with possible toxicity, including risk factors, physical find- may be induced by statins. ings, and consideration of alternate diagnoses. Since there is no single test to diagnose statin- In patients with possible statin-induced myopathy, assess- induced myopathy, we offer a framework to ing the risks and benefits of statin therapy is essential. aid clinicians in stratifying patients based on the likelihood that their symptoms are due to For patients who cannot tolerate statin therapy, alternatives statin toxicity weighed against the likelihood include a “statin holiday” followed by a rechallenge with a that they will benefit from statin therapy. different statin, intermittent rosuvastatin (Crestor), or resin therapy. Sometimes the best alternative is a compromise be- ■ DEFINITIONS DIFFER tween the goal level for low-density-lipoprotein cholesterol and the level achievable with alternative therapy. Little consensus exists on how to define the adverse muscle effects of statins,5 which may doi:10.3949/ccjm.78a.10073 contribute to the underdiagnosis of this com- CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 78 • NUMBER 6 JUNE 2011 393 Downloaded from www.ccjm.org on October 2, 2021. For personal use only. All other uses require permission. STATIN MYOPATHY plication. The magnitude of creatine kinase Another reason is that these trials were (CK) elevation required to define rhabdomy- designed to assess the efficacy of statins and olysis has increased from 500 IU/L in 1982,6 were not sensitive to adverse effects like mus- to 1,000 IU/L in 1988,7 to 50 times the upper cle pain. When they looked at myopathy, they limit of normal in one current definition.8 The focused on rhabdomyolysis—the most severe American Heart Association, the American form—rather than on myalgia, fatigue, or College of Cardiology, the National Heart other minor muscle complaints.15 Addition- Lung and Blood Institute,9 the National Lipid ally, most trials enrolled too few patients and Association,8 and the US Food and Drug Ad- did not have long enough follow-up to reveal ministration10 all differ in their definitions. infrequent toxicities. Despite the strict criteria, a significant Our definitions number of trial patients discontinued statin For the purpose of this article, we offer the fol- therapy during the study period. In the Treat lowing definitions: to New Targets (TNT) trial, 5% of patients Myalgia—muscle weakness, soreness, tender- in both the high- and low-dose atorvastatin ness, stiffness, cramping, or aching, either at rest (Lipitor) groups experienced muscle toxicity, or with exertion, without any elevation in CK. even though 35% of eligible patients had been Myositis—elevated CK with or without excluded during the open-label run-in phase.14 muscle symptoms. The “-itis” suffix is unfor- Also, physicians may overlook and pa- tunate since myositis does not correspond to tients may fail to report symptoms such as inflammation on biopsy. fatigue, malaise, or dyspnea that are not com- Rhabdomyolysis—muscle symptoms with monly accepted as signs of statin toxicity.16 a CK level 10 times the upper limit of normal or higher. Evidence of renal dysfunction is not Findings from observational studies required for the diagnosis, as preexisting renal Observational studies in nonselected outpa- disease and hydration status are more closely tients show a higher frequency of muscle com- related to kidney damage than the degree of plaints in the statin groups than in the control In observational muscle injury.11 groups. These studies suggest the frequency of studies, muscle statin myopathy is 9% to 20%.17–19 ■ STATIN MYOPATHY IS MORE COMMON The Prediction of Muscular Risk in Ob- symptoms IN THE REAL WORLD THAN IN TRIALS servational Conditions (PRIMO) study20 was occurred one of the largest and best-defined observa- in up to 20% The incidence of statin-induced myopathy is tional studies of muscular symptoms in an un- significantly lower in randomized controlled selected population. It included 7,924 French of patients trials of statin efficacy than in observational outpatients with hypercholesterolemia, ages on statins studies of real-world patients. In randomized 18 to 75 years, on high-dose statins for 3 or clinical trials, myalgia was reported in 1% to more months before the study. Daily statin 5% of patients in the statin groups and pla- regimens included atorvastatin 40 to 80 mg, cebo groups alike,9,12 whereas clinical practice fluvastatin (Lescol) 80 mg, pravastatin (Prava- would suggest it is more common. chol) 40 mg, and simvastatin (Zocor) 40 to 80 mg. In this study, 10.5% of patients reported Why is statin-induced myopathy muscle-related symptoms. so uncommon in clinical trials? Buettner et al,21 in another cross-sectional A reason may be that patients in clinical trials study, interviewed and examined 3,580 adults are carefully screened. To minimize toxicity, over age 40. Of those taking statins, 22% re- the clinical trials of statins excluded patients ported having had musculoskeletal pain in at with renal insufficiency, hepatic insufficiency, least one anatomic region in the last 30 days, a history of muscular complaints, and poorly compared with 16.7% of those not taking a controlled diabetes, as well as patients taking statin. drugs with possible interactions. Large efficacy In the United States, where an estimated trials have excluded up to 30% of the partici- 33 million adults use statins, musculoskeletal pants in active prerandomization phases.13,14 pain can be expected to occur in 7 million 394 CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 78 • NUMBER 6 JUNE 2011 Downloaded from www.ccjm.org on October 2, 2021. For personal use only. All other uses require permission. FERNANDEZ AND COLLEAGUES people, likely induced by statin therapy in 22 LDL-C reduction and creatine kinase (CK) elevation 25% of cases. 2.5 Cerivastatin (Baycol) ■ WHAT CAUSES STATIN MYOPATHY? 0.8 mg 2.0 The causes of statin-induced myopathy are 1.5 0.4 mg Simvastatin poorly understood. (Zocor) Atorvastatin Pravastatin 80 mg Historically, statin-induced toxicity was (Lipitor) 1.0 (Pravachol) 40 80 mg thought to be caused by inhibition of the syn- mg 20 thesis of mevalonate, leading to depletion of mg 40 mg Rosuvastatin (Crestor) 0.5 10 mg 0.2 mg 40 mg its metabolites, such as cholesterol, isopren- 10 mg 20 mg 0.3 20 mg oids, and ubiquinone (coenzyme Q10). De- Occurrence of CK >10 x ULN (%) mg 40 mg 0.0 pletion of intracellular cholesterol may lead 20 25 30 35 40 5045 6055 7065 to abnormal membrane behaviors; depletion % Reduction in low-density lipoprotein cholesterol (LDL–C) of isoprenoids may affect intracellular signal- ing; depletion of coenzyme Q10 may in turn FIGURE 1 reduce mitochondrial respiratory function. REPRINTED FROM BREwER HB JR. BENEFIT-RIsk AssEssMENT OF ROsuvastatin 10 TO 40 MILLIgRAMs. AM J CARDIOL 2003; 92(sUPPL):23k–29k, Genetic factors may also play a role, contrib- COPyRIgHT 2003, wITH PERMIssION FROM ELsEVIER; uting to pharmacokinetics and predisposing www.sCIENCEDIRECT.COM/sCIENCE/JOURNAL/ 00029149. metabolic muscle disorders.23,24 Statin-induced myopathy seems to be that lessens the lipid substrate available to different in randomized efficacy trials than muscle rather than from the reduction of in the clinical setting. In randomized trials, products downstream from mevalonate by the mechanism appears to involve abnormal statins.
Load more

Recommended publications
  • SUPPLEMENTARY MATERIAL Supplementary 1. International
    SUPPLEMENTARY MATERIAL Supplementary 1. International Myositis Classification Criteria Project Steering Committee Supplementary 2. Pilot study Supplementary 3. International Myositis Classification Criteria Project questionnaire Supplementary 4. Glossary and definitions for the International Myositis Classification Criteria Project questionnaire Supplementary 5. Adult comparator cases in the International Myositis Classification Criteria Project dataset Supplementary 6. Juvenile comparator cases in the International Myositis Classification Criteria Project dataset Supplementary 7. Validation cohort from the Euromyositis register Supplementary 8. Validation cohort from the Juvenile dermatomyositis cohort biomarker study and repository (UK and Ireland) 1 Supplementary 1. International Myositis Classification Criteria Project Steering Committee Name Affiliation Lars Alfredsson Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden Anthony A Amato Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA Richard J Barohn Department of Neurology, University of Kansas Medical Center, Kansas City, USA Matteo Bottai Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden Matthew H Liang Division of Rheumatology, Immunology and Allergy, Brigham and Women´s Hospital, Boston, USA Ingrid E Lundberg (Project Director) Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden Frederick W Miller Environmental
    [Show full text]
  • EM Guidemap - Myopathy and Myoglobulinuria
    myopathy EM guidemap - Myopathy and myoglobulinuria Click on any of the headings or subheadings to rapidly navigate to the relevant section of the guidemap Introduction General principles ● endocrine myopathy ● toxic myopathy ● periodic paralyses ● myoglobinuria Introduction - this short guidemap supplements the neuromuscular weakness guidemap and offers the reader supplementary information on myopathies, and a short section on myoglobulinuria - this guidemap only consists of a few brief checklists of "causes of the different types of myopathy" that an emergency physician may encounter in clinical practice when dealing with a patient with acute/subacute muscular weakness General principles - a myopathy is suggested when generalized muscle weakness involves large proximal muscle groups, especially around the shoulder and proximal girdle, and when the diffuse muscle weakness is associated with normal tendon reflexes and no sensory findings - a simple classification of myopathy:- Hereditary ● muscular dystrophies ● congenital myopathies http://www.homestead.com/emguidemaps/files/myopathy.html (1 of 13)8/20/2004 5:14:27 PM myopathy ● myotonias ● channelopathies (periodic paralysis syndromes) ● metabolic myopathies ● mitochondrial myopathies Acquired ● inflammatory myopathy ● endocrine myopathies ● drug-induced/toxic myopathies ● myopathy associated with systemic illness - a myopathy can present with fixed weakness (muscular dystrophy, inflammatory myopathy) or episodic weakness (periodic paralysis due to a channelopathy, metabolic myopathy
    [Show full text]
  • Connective Tissue 5.2.04
    Other Connective Tissue Diseases Chester V. Oddis, MD Thomas A. Medsger, Jr, MD Arthur Weinstein, MD Contents 1. Undifferentiated Connective Tissue Disease 2. Idiopathic Inflammatory Myopathy 3. Scleroderma 4. Sjögren’s Syndrome 5. References OTHER CONNECTIVE TISSUE DISEASES 1 1. Undifferentiated Connective Tissue Disease Table 1 The American College of Rheumatology (ACR) has published criteria for several different diseases Clinical Features and Autoantibody Findings commonly referred to as connective tissue disease Possibly Specific for a Defined CTD (CTD). The primary aim of such classification crite - ria is to ensure the comparability among CTD stud - ies in the scientific community. These diseases Clinical Feature include rheumatoid arthritis (RA), systemic sclero - sis (SSc), systemic lupus erythematosus (SLE), Malar rash polymyositis (PM), dermatomyositis (DM), and Sjögren’s syndrome (SS). These are systemic Subacute cutaneous lupus rheumatic diseases which reflects their inflamma - tory nature and protean clinical manifestations with Sclerodermatous skin changes resultant tissue injury. Although there are unifying immunologic features that pathogenetically tie Heliotrope rash these separate CTDs to each other, the individual disorders often remain clinically and even serologi - Gottron’s papules cally distinct. Immunogenetic data and autoanti - body findings in the different CTDs lend further Erosive arthritis support for their distinctive identity and often serves to subset the individual CTD even further, as seen with the myositis syndromes, SLE and SSc. In other cases, it remains difficult to classify individuals Autoantibody with a combination of signs, symptoms, and labora - tory test results. It is this group of patients that have Anti-dsDNA an “undifferentiated” connective tissue disease (UCTD), or perhaps more accurately, an undifferen - Anti-Sm tiated systemic rheumatic disease.
    [Show full text]
  • Occupational Diseases
    OCCUPATIONAL DISEASES OCCUPATIONAL DISEASES ОДЕСЬКИЙ ДЕРЖАВНИЙ МЕДИЧНИЙ УНІВЕРСИТЕТ THE ODESSA STATE MEDICAL UNIVERSITY Áiáëiîòåêà ñòóäåíòà-ìåäèêà Medical Student’s Library Започатковано 1999 р. на честь 100-річчя Одеського державного медичного університету (1900–2000 рр.) Initiated in 1999 to mark the Centenary of the Odessa State Medical University (1900–2000) 1 OCCUPATIONAL DISEASES Recommended by the Central Methodical Committee for Higher Medical Education of the Ministry of Health of Ukraine as a manual for students of higher medical educational establishments of the IV level of accreditation using English Odessa The Odessa State Medical University 2009 BBC 54.1,7я73 UDC 616-057(075.8) Authors: O. M. Ignatyev, N. A. Matsegora, T. O. Yermolenko, T. P. Oparina, K. A. Yarmula, Yu. M. Vorokhta Reviewers: Professor G. A. Bondarenko, the head of the Department of Occupational Diseases and Radiation Medicine of the Donetzk Medical University named after M. Gorky, MD Professor I. F. Kostyuk, the head of the Department of Internal and Occupational Diseases of the Kharkiv State Medical University, MD This manual contains information about etiology, epidemiology, patho- genesis of occupational diseases, classifications, new methods of exami- nation, clinical forms and presentation, differential diagnosis, complica- tions and treatment. It includes the questions of prophylaxis, modern trends in treatment according to WHO adopted instructions, working capacity expert exam. The represented material is composed according to occupational dis- eases study programme and it is recommended for the students of higher medical educational establishments of the IV accreditation standard and doctors of various specialities. Рекомендовано Центральним методичним кабінетом з вищої медичної освіти МОЗ України як навчальний посібник для студентів вищих медичних навчальних закладів IV рівня акредитації, які опановують навчальну дисципліну англiйською мовою (Протокол № 4 від 24.12.2007 р.
    [Show full text]
  • Notes on Rheumatology Author: Liz Tatman © Dr R
    Notes on Rheumatology Author: Liz Tatman Musculoskeletal (MSK) Problems: Principles of Management MSK symptoms Pain – site, radiation (get radiation distally, more common with more proximal joints e.g. shoulder and knee), quality (shooting with nerve entrapment). Onset. With usage (mechanical), at rest (inflammatory) or at night (if no relation to movement concern about bony mets). Bony pain – well localised, doesn’t radiate, progressive, night predominant, not related to movement, due to fractures, neoplasia, Paget’s disease, osteomalacia, osteomyelitis, osteonecrosis. Referred pain – poorly localised, diffuse, improved by rubbing. Can get neuropathic pain sometime after injury. Stress pain – in tight pack positions, if in all directions suggests synovitis. Stiffness – prolonged early morning and inactivity imply inflammatory cause. Swelling and deformity. Instability Locking – sudden inability to move joint, usually painful but transient, post unlocking discomfort. Affects hinge joints (knee, elbow, TMJ). Mechanical problem e.g. synovium, cartilage, split meniscus. Loss of function, disability and handicap. Systemic illness – night sweats, malaise, fatigue, weight loss suggest inflammatory process. Sleep disturbance. Red flags: progressive, well localised progressive night-predominant pain (mets), red hot joint (sepsis), sequential joint involvement (spreading sepsis). History – need to determine if traumatic or non-traumatic, ask about dominant hand. Trauma – time, place, mechanism (twist, blow, crush), magnitude of force, direction of force, first aid, immediate symptoms and progression, previous injuries. Non-trauma – rule out (RESTIT) Referred pain, Embolus, Sepsis, Tumour, Ischaemia, Thrombosis. Systems enquiry for non MSK causes, associated features, drug toxicity, pre-op assessment and involvement of other organs. Especially general malaise (anaemia), hot and shivery (infection), skin (rashes, psoriasis, Raynaud’s), eyes (iritis, scleritis).
    [Show full text]
  • General Disease Finder 455
    453 General disease finder 455 This overview will help to find neuromuscular disease patterns in the different sections Cushing‘s disease: steroid myopathy Adrenal dysfunction Addison’s disease: general muscle weakness Periodic paralysis Aldosteronism Tetanic muscles CN: VII AIDS Polyneuropathies: inflammatory, immune mediated, treatment related Myopathies: inflammatory, treatment related Neoplastic: Lymphoma (direct invasion) Opportunistic infections: CMV, Toxoplasmosis, Cryptococcus, HSV, Candida, Varicella, Histoplasma, TBC, Aspergillus CMV polyradiculomyelopathy Herpes zoster radiculitis Syphilitic radiculopathy Treatment related: polyneuropathy/myopathy Ddl, ddC, Foscarnet, Isoniazid Zidovudine Polyneuropathy (distal, rarely proximal, rare ulcers) Alcoholism Mononeuropathy-radial nerve (compression) Myopathy Acute necrotizing myopathy and myoglobinuria Chronic proximal weakness Hypokalemic paralysis Myoglobinuria Compartment syndromes (prolonged compression) Familial amyloid polyneuropathies Amyloid Transthyretin Sensorimotor neuropathy Autonomic involvement Apolipoprotein A-1 Polyneuropathy, painful, hearing loss Gelsolin type V, VII and other CN Mild polyneuropathy Primary amyloidosis (AL) Deposition of immunoglobulin light chains in tissue 456 Painful neuropathy Autonomic involvement Carpal tunnel syndrome Muscle amyloid Amyloidoma (trigeminal root) Secondary or reactive amyloidosis (AA) Chronic inflammatory diseases, rheumatoid diseases, osteomyelitis Deposition of acute phase plasma protein, serum amyloid A: polyneuropathy not
    [Show full text]
  • 432 Medicine Team Leaders 1St Questions: D Raghad Al Mutlaq & Abdulrahman Al Zahrani 2Nd Questions: D for Mistakes Or Feedback: [email protected]
    MEDICINE 432 Team 51 Myopathies Done By: Reviewed By: Abdurahman Alakeel Sarah Al-Essa COLOR GUIDE: • Females' Notes • Males' Notes • Important • Additional 432MedicineTeam Myopathies Objectives Not Given 1 432MedicineTeam Myopathies Myopathies: • Myo -is muscle, pathos is suffering in Greek • Disorders in which there is a primary functional (like problems in ion channels) or structural (destruction of muscle tissue replaced by connective tissue or fat) impairment of skeletal muscle. • Helpful link: https://www.youtube.com/watch?v=8wa04qYsaps Approach: • THREE STEPS: 1. Distinguishing true muscle weakness from other symptoms. • Distinguishing type of pain or weakness is the first step in evaluating patients with muscle-related complaints. • SOB (shortness of breath), joint pain (asthenia), fatigue, poor exercise tolerance, or paresthesia, rather than a true muscle weakness. • Heart failure, arthritis, depression… Asthenia: 2. Distinguishing CNS from PNS lesions. (PNS lesions present bilaterally) Motor impairment do to pain or joint 3. Determining the etiology. dysfunction SYMPTOMS: • Positive symptoms: Myalgia ,myotonia ,cramps ,contractures ,myoglobinuria. • Negative symptoms: Weakness, atrophy, exercise intolerance, periodic paralysis. 2 432MedicineTeam Myopathies 1- Weakness • Weakness is the cardinal symptom • The distribution of weakness is variable and may change over time . • Most of the time in the proximal muscles; muscles of the shoulder girdle. • Patients complain from difficulty arising from a chair or low toilet, difficulty climbing stairs, a waddling gait, difficulty lifting objects over the head, combing hair or brushing teeth. • Distal weakness is less common. • Patients with proximal leg weakness may rise from sitting on the floor by “climbing up their legs with their hands”, This is termed Gower's Gower’s sign sign.
    [Show full text]
  • Opmaak 1 5/10/11 12:33 Pagina 563
    finsterer-_Opmaak 1 5/10/11 12:33 Pagina 563 Acta Orthop. Belg. , 2011, 77 , 563-582 REVIEW ARTICLE Orthopaedic abnormalities in primary myopathies Josef FiNStErEr , Walter StrOBl From Krankenanstalt Rudolfstiftung and Orthopaedic Hospital Speising, Vienna, Austria Orthopaedic abnormalities are frequently recognised Keywords : myopathy ; muscular dystrophy ; neuro - in patients with myopathy but are hardly systemati - muscular disorder ; orthopaedic disorders ; surgery. cally reviewed with regard to type of myopathy, type of orthopaedic problem, and orthopaedic manage - ment. this review aims to summarize recent findings and current knowledge about orthopaedic abnormal - List Of abbreviatiOns ities in these patients, their frequency, and possible therapeutic interventions. AMC Arthrogryposis multiplex congenita a MeDLine search for the combination of specific BMD Becker muscular dystrophy terms was carried out and appropriate articles CCD Central core disease were reviewed for the type of myopathy, types of CMD Congenital muscular dystrophy orthopaedic abnormalities, frequency of orthopaedic CMP Congenital myopathy abnormalities, and possible therapeutic interven - DHS Dropped head syndrome tions. DMD Duchenne muscular dystrophy Orthopaedic abnormalities in myopathies can be EDMD Emery-Dreifuss muscular dystrophy most simply classified according to the anatomical FHl1 Four-and-a-half Lin11, isl-1, Mec-3-domain 1 location into those of : the spine, including dropped gene head, camptocormia, scoliosis, hyperlordosis, hyper - FSH Facioscapulohumeral muscular dystrophy kyphosis, or rigid spine ; the thorax, including pectus lGMD limb girdle muscular dystrophy excavatum (cobbler’s chest), anterior/posterior flat - lMNA lamin A/C tening, or pectus carinatum (pigeon’s chest) ; the MD1 Myotonic dystrophy 1 limb girdles, including scapular winging and pelvic MD Muscular dystrophy deformities ; and the extremities, including con - MP Myopathy tractures, hyperlaxity of joints, and hand or foot MYH Myosin heavy chain deformities.
    [Show full text]
  • CLINICAL REVIEW Statin Induced Myopathy
    For the full versions of these articles see bmj.com CLINICAL REVIEW Statin induced myopathy Sivakumar Sathasivam, Bryan Lecky Department of Neurology, Walton Since their introduction for the treatment of hyper- with exercise. In a small retrospective study of 45 Centre for Neurology and cholesterolaemia in 1987, the use of statins has grown patients, the mean duration of statin therapy before onset Neurosurgery, Liverpool L9 7LJ to over 100 million prescriptions per year.1 About of symptoms was 6.3 (SD 9.3) months (range 1 week to Correspondence to: S Sathasivam sivakumar. 1.5-3% of statin users in randomised controlled trials 4 years). In this study, the mean duration of myalgia after sathasivam@thewaltoncentre. and up to 10-13% of participants enrolled in prospec- stopping statin therapy was 2.3 (SD 3.0) months (range nhs.uk tive clinical studies develop myalgia.1-4 As a conserva- 1 week to 4 months).7 Muscle symptoms that develop in a Cite this as: BMJ 2008;337:a2286 tive estimate, at least 1.5 million people per year will patient who has been taking statins for several years are doi:10.1136/bmj.a2286 experience a muscle related adverse event while taking unlikely to have been caused by these drugs. a statin. In this review we discuss statin induced myopathy and its management in the light of recent What are the proposed mechanisms of statin induced epidemiological studies, randomised controlled trials, myopathy? and guidelines. The mechanism of statin induced myopathy is unknown. One proposal is that impaired synthesis of How common
    [Show full text]
  • Pediatric Pathology Major Category Code Headings 1 Perinatal
    updated 8/20/2021 Pediatric Pathology Page 1 of 25 Pediatric Pathology Major Category Code Headings Revised 8/17/2021 1 Perinatal Pathology: Placental-maternal-fetal relationships in pregnancy 70000 2 Perinatal Pathology: Fetal/Neonatal pathophysiology 70445 3 General Pathologic Principles and Syndromes, NOS 70645 4 Cardiovascular System, NOS 70815 5 Respiratory System and Mediastinum, NOS 71050 6 Central Nervous System, NOS 71255 7 Skin, NOS 71455 8 Special Senses – Eye and Ear 71680 9 Alimentary Tract, NOS 71800 10 Hepatobiliary System and Pancreas, NOS 72225 11 Kidney and Urinary System, NOS 72585 12 Endocrine system, excluding ovary and testis, NOS 72825 Hematopoietic system, including bone marrow, lymph nodes, thymus, spleen 13 and other lymphoid tissues 72945 14 Breast, NOS 73220 15 Female reproductive system, NOS 73275 16 Disorders of sexual development (Intersex disorders), NOS 73445 17 Male reproductive system, NOS 73530 18 Soft tissue, peripheral nerve and muscle, NOS 73690 19 Skeletal system, NOS 74005 20 Diagnostic/Technical Procedures, Laboratory Management 74120 21 Admin. & Management, LIS, QA, Lab Planning, Regulations & Safety 74775 22 Forensic Pathology, NOS 74850 Pediatric Pathology Page 2 of 25 Pediatric Pathology 1 Perinatal Pathology: Placental-maternal-fetal relationships in pregnancy 70000 A Conception 70005 1 Gametogenesis 70010 2 Fertilization 70015 3 Implantation 70020 B Normal embryonic and fetal development, NOS 70025 1 Embryologic processes 70030 2 Normal histology of fetal organs 70035 C Pregnancy physiology
    [Show full text]
  • Criteria for the Classification and Diagnosis of the Rheumatic Diseases
    APPENDIX I Criteria for the Classifi cation and Diagnosis of the Rheumatic Diseases The criteria presented in the following section have The proposed criteria are empiric and not intended been developed with several different purposes in mind. to include or exclude a particular diagnosis in any indi- For a given disorder, one may have criteria for (1) clas- vidual patient. They are valuable in offering a standard sifi cation of groups of patients (e.g., for population to permit comparison of groups of patients from differ- surveys, selection of patients for therapeutic trials, or ent centers that take part in various clinical investiga- analysis of results on interinstitutional patient compari- tions, including therapeutic trials. sons); (2) diagnosis of individual patients; and (3) esti- The ideal criterion is absolutely sensitive (i.e., all mations of disease frequency, severity, and outcome. patients with the disorder show this physical fi nding or The original intention was to propose criteria as the positive laboratory test) and absolutely specifi c guidelines for classifi cation of disease syndromes for the (i.e., the positive fi nding or test is never present in any purpose of assuring correctness of diagnosis in patients other disease). Unfortunately, few such criteria or sets taking part in clinical investigation rather than for indi- of criteria exist. Usually, the greater the sensitivity of a vidual patient diagnosis. However, the proposed criteria fi nding, the lower its specifi city, and vice versa. When have in fact been used as guidelines for patient diagno- criteria are established attempts are made to select rea- sis as well as for research classifi cation.
    [Show full text]
  • Guiding Medical Accession Standards for the Commissioned Corps of the U.S
    Guiding Medical Accession Standards for the Commissioned Corps of the U.S. Public Health Service CCPM Pamphlet No. 46 Disqualifying Medical and Dental Conditions Table of Contents Condition Page I. Head and Neck…………………………………………………………………………… 2 II. Mouth, Nose, Larynx and Trachea…………………………………………………… 3 III. Dental Disorders…………………………………………………………..…………… 4 IV. Eyes and Vision………………………………………………………………………... 5 V. Ears and Hearing…………………………………………………………...…………… 8 VI. Cardiovascular Disorders………………………………………………….…………… 9 VII. Pulmonary Disorders……………………………………………………..…………… 12 VIII. Gastrointestinal and Hepatobiliary Disorders…………………………...………… 14 IX. Endocrine and Metabolic Disorders…………………………………………………… 17 X. Hematological Disorders…………………………………………………..…………… 19 XI. Renal and Urologic Disorders…………………………………………….…………… 21 XII. Gynecological Disorders and Breast Disease……………………………………… 24 XIII. Musculoskeletal and Rheumatologic Disorders………………………..…………… 26 XIV. Skin Disorders………………………………………………………….……………… 33 XV. Infectious Diseases…………………………………………………………………… 36 XVI. Immunologic Disorders……………………………………………………………… 37 XVII. Neoplastic Disorders…………………………………………………...…………… 39 XVIII. Neurologic and Muscle Disorders…………………………………….…………… 40 XIX. Mental Disorders………………………………………………………..…………… 43 XX. Substance Use and Addictive Behaviors…………………………………………… 46 XXI. Miscellaneous…………………………………………………………...…………… 47 1 Guiding Medical Accession Standards for the Commissioned Corps of the U.S. Public Health Service CCPM Pamphlet No. 46 Condition Disqualification for Appointment I.
    [Show full text]